Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose: The purpose of the study was to assess the efficacy and safety of biweekly oxaliplatin in combination with leucovorin (LV)-modulated bolus plus infusion of 5-fluorouracil (5-FU) in patients with relapsed or metastatic colorectal cancer (CRC) as a second line therapy. Materials and Methods: Between November 2002 and October 2005, 26 patients with histologically confirmed relapsed or metastatic CRC were enrolled. All patients were previously treated with irinotecan-based combination chemotherapy. The chemotherapy regimen consisted of oxaliplatin 85 mg/m2 on day 1; LV 200 mg/m2 on days 1 and 2; and 5-FU 400 mg/m2 bolus IV with 600 mg/m2 with a 22-hour infusion on days 1 and 2 every 2 weeks. Results: The median age of the 26 patients was 50.5 years (range, 31～72). Their metastatic sites included: the liver (42.3%), peritoneum (26.9%), lung (23.1%) and ovary (7.7%). Twenty five patients were evaluated for their response. Four patients achieved partial responses and 15 patients had stable disease. The overall response rate was 16% (95% confidence interval; 1.7～30.3%). The median follow-up duration for the surviving patients was 7.4 months (range, 2.08～21.2). Median overall survival (OS) and 1-year OS rates were 16.7 months and 63.9%, respectively. The most common hematological toxicities were: NCI grade I/II leucopenia (49.3%), grade I/II neutropenia (41%) and grade I/II anemia (65.2%). The main non-hematological toxicities were: grade I/II peripheral neuropathy (16.1% and 21.5%, respectively) and nausea/ vomiting (23.6%/18.5%). There was no life-threatening toxicity. Conclusion: The oxaliplatin, 5-FU and LV combination chemotherapy, scheduled as a biweekly protocol, was effective and well tolerated in the treatment of relapsed or metastatic colorectal cancer patients as second line chemotherapy. (Cancer Res Treat. 2006;38:201-205)
참고문헌 (20)
- "A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma", 80, pp.1179~1187 (1997)
- "Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer", 306, pp.752~5 (1993)
- "Antitumor activity of 7-ethyl-10-[4- a novel water-soluble derivative of camptothecin", 1-piperidi, pp.5944~7 (1987)
- "Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy", 15, pp.251~260 (1997)
- "Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen)", 17, pp.2901~2908 (1999)
- "Oxaliplatin: mechanism of action and antineoplastic activity", 25, pp.4~12 (1998)
- "Oxaliplatin, tetraplatin, cisplatin, and carboplatin", 52, pp.1855~1865 (1996)
- "Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients", 16, pp.2739~2744 (1998)
- "Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines", 7, pp.95~98 (1996)
- "Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)", 25, pp.627~631 (2002)
- "Phase I study of oxaliplatin in patients with advanced cancer", miq(t l), pp.299~303 (1990)
- "Oxaliplatin as single agent in previously untreated colorectal carcinoma patients", 9, pp.105~108 (1998)
- "Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer", 61, pp.36~41 (2001)
- "Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen", 17, pp.3560~3568 (1999)
- "Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer", 18, pp.136~147 (2000)
- "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", 18, pp.2938~2947 (2000)
- "FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer", 22, pp.229~237 (2004)
- "Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin", 21, pp.2059~2069 (2003)
- "High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)", 37, pp.1000~1005 (2001)
- "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", 350, pp.2343~2351 (2004)